Tiefenbacher Group Football Cup 2025
The Tiefenbacher Group Football Cup 2025 winner is “The Lawn Mowers”
This year, more than 200 people (employees and their families) turned up to join the Tiefenbacher Group Football Cup. They spent a wonderful sunny day full of team spirit, playing football together and great vibes.
After a gripping group stage, the final saw “The Lawn Mowers” take on “Red Flags”, with “The Lawn Mowers” clinching the win in a 3:1 victory! Congratulations Paul-Kester Schulz, Katharina Wolff, Hassan Tufail, Oliver Schrader 🇺🇦, Meelad Akam, Jennifer Detlefsen, Kristian Ruepp, and Richard Baderin for winning this year’s Tiefenbacher Cup!
The atmosphere was simply incredible
A huge thank you to Ulrike Klingberg & Florian Herb for organizing such a fantastic event, and of course to everyone who helped make it happen behind the scenes.
With food, drinks, and music rounding off the day, the atmosphere was simply incredible. We’re already counting down the days to next year’s tournament!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
Tiefenbacher Group Celebrates Pharmacy Day
Last Saturday, Germany celebrated Pharmacy Day - Tag der Apotheke!
We at Tiefenbacher Group want to take this moment to thank all pharmacists for their invaluable contribution to global health. Every day, your expertise and commitment make a critical difference in people’s lives.
As a fully integrated pharmaceutical company, we are proud to have many pharmacists in our team, playing essential roles along the entire pharmaceutical value chain – from research & development to the local pharmacy counter. Thank you for your pioneering spirit, expertise, and relentless commitment to advancing healthcare!
Pharmacists Without Borders
We are especially proud to constantly support the non-profit organization Apotheker ohne Grenzen Deutschland e.V. | Pharmacists without borders Germany which is currently delivering vital medicines to Ukraine. Together, we remain committed to bringing help where it is needed most – for a healthier world.
Tiefenbacher Group World Environment Day
World Environment Day 2025 – Our Commitment to a Healthier Planet
June 5 marks World Environment Day, established by the United Nations in 1972 to raise global awareness and inspire action for the protection of our environment. This year’s motto is “Restore Our Earth”, highlighting the urgent need to reverse environmental degradation and build a more sustainable future.
At Tiefenbacher Group, this mission is close to our heart. As a purpose-driven healthcare company, we believe that protecting human health begins with protecting the planet.
We’re proud to share that we’ve reduced our corporate carbon footprint from 7,106 t CO₂e in 2023 to just 2,223 t CO₂e in 2024 which means a 69 % reduction over the past year. This was achieved through concrete actions: switching to green electricity at all locations, generating solar power at our Cyprus site, and fully offsetting business travel emissions through certified climate projects.
It makes sense in many ways
Our commitment not only protects the climate, but also makes economic sense: With a projected CO₂ price of 55 euros per ton, our reduction would mean annual savings of over 250,000 euros. To reach climate neutrality (scope 1 & 2), we’re now phasing out fossil fuels, transitioning to electric vehicles, and further improving energy efficiency across our sites. On this World Environment Day, we renew our commitment to climate action for the health of our planet and the well-being of future generations.
We’re proud to share that we’ve reduced our corporate carbon footprint from 7,106 t CO₂e in 2023 to just 2,223 t CO₂e in 2024 which means a 69 % reduction over the past year. This was achieved through concrete actions: switching to green electricity at all locations, generating solar power at our Cyprus site, and fully offsetting business travel emissions through certified climate projects.
Tiefenbacher Group celebrating new buildings in Hyderabad
Exciting News from Tiefenbacher Group!
We are thrilled to announce the grand inauguration of our newly constructed development and production facilities in Hyderabad, India! This marks a significant milestone in our mission to develop and manufacture high-quality, affordable pharmaceuticals for patients worldwide.
Our new facilities
Our state-of-the-art complex spans 4,000 m², featuring cutting-edge laboratories and production facilities designed to meet the highest safety and GxP compliance standards. The new facilities provide product development labs, analytical labs, administrative offices, and an employee canteen. A key highlight is our new oncology drug production unit, enabling us to expand our specialty pharmaceuticals portfolio. With over 20 leading highly potent oncology drugs in our launch pipeline, this investment strengthens our role as an innovation leader in the industry. Additionally, we held a groundbreaking ceremony for the expansion of the Production Block 1 which is used for other pharmaceuticals indications.
Festive inauguration ceremony
This memorable event was graced by our esteemed managing directors, Tiefenbacher family shareholders, and advisory board members. To mark this special occasion, we hosted a festive inauguration ceremony at our Hyderabad site, bringing together our employees, leadership team, and distinguished guests. The celebration featured inspiring speeches by our leadership team, including Swapnil Singh, Sandip Tarate, Oliver Schrader & Dr. Kristian Ruepp, as well as honored dignitaries, recognition of our dedicated project team, a vibrant cultural show, a live band performance, and a delightful dinner.
Tiefenbacher Group’s commitment
This expansion and celebration underscore Tiefenbacher Group’s commitment to innovation and excellence as a fully integrated global pharmaceutical company. Our Hyderabad site continues to set industry benchmarks with its advanced technologies, stringent quality standards, and dedication to improving global healthcare. A big thank you to our incredible team and partners who made this possible!
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Group, OnDosis and Star celebrate iF Design Award for OYSTA
We are proud to announce that OYSTA has been honored with the prestigious iF Design Award for its excellence in digital innovation and user-centric design.
This award is a testament to our shared vision and collaborative efforts of our partners—global life science company OnDosis AB and global technology consultancy Star—to redefine medication management for ADHD and beyond.
Improving ADHD care with digital innovation
OYSTA is more than a product—it’s a transformative solution designed to support medication adherence and enhance the care experience for young patients. By combining pharmaceutical expertise with e-health technology, OYSTA integrates two key components: the OYSTA Dosage Manager and the OYSTA Digital Service. Together, they enable intuitive, precise and flexible dosing, while providing connected care for patients, healthcare providers, teachers and carers.
The OYSTA Digital Service empowers effective ADHD management through tools for medication adherence, real-time data tracking and personalized insights. This breakthrough in personalized medication management improves the treatment experience for young patients and their circle of care.
A collaborative achievement setting a new standard in digital health
This transformative solution was made possible through the collaboration of OnDosis, who led its development, Tiefenbacher Group, which contributed its pharmaceutical expertise, and Star, which designed and built the OYSTA Digital Service—ensuring seamless integration between the physical dosing device and the digital ecosystem.
ADHD treatment is a complex, highly individualized process that requires precise dosage adjustments and continuous monitoring. OYSTA exemplifies an innovative healthcare solution that not only meets medical and technical standards. It also prioritizes the needs of patients and healthcare providers. This milestone reflects our collective dedication to creating a patient-centric solution that sets a new standard in digital health—one that is both effective and accessible.
For more information about OYSTA, visit oysta-health.com.
Explore the work of our partners OnDosis at https://www.ondosis.com/ and Star at star.global
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Lindus Health and Tiefenbacher Group Launching Clinical Trial
Lindus Health and Tiefenbacher Group are launching a clinical trial to advance ME/CFS research and treatment. At Tiefenbacher Group, we are committed to driving innovation in healthcare and addressing unmet medical needs.
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a serious and complex chronic condition affecting multiple body systems. Characterized by severe fatigue, post-exertional malaise (PEM), cognitive impairment, and other debilitating symptoms, ME/CFS significantly impacts the quality of life of those affected. Despite its prevalence of approximately 1%, there are currently no disease-targeted medications available, highlighting an urgent need for therapeutic advancements.
Research and Complexity
Understanding the complexity of ME/CFS requires a multi-faceted approach. Research suggests that potential triggers may include viral infections, immune system dysfunction, hormonal imbalances, and genetic predispositions. However, the exact pathophysiology remains unclear. This underscores the necessity of robust scientific exploration to identify novel treatment strategies that can alleviate symptoms and improve patient outcomes.
Research Efforts
Our commitment to pioneering healthcare is exemplified by our latest research efforts focused on ME/CFS. We aim to develop innovative treatment solutions that not only target symptoms but also address underlying disease mechanisms. By leveraging our expertise in pharmaceutical development and working alongside leading researchers, we strive to make a tangible difference in the lives of patients suffering from this debilitating condition.
Collaboration and Study Model
Collaboration is key to accelerating progress, which is why we are proud to partner with Lindus Health. Our ME/CFS study will leverage their decentralized clinical trial (DCT) model, allowing participants to move through screening, recruitment, and study procedures remotely from their homes. This approach enhances patient experience by providing greater flexibility and convenience. Recruitment will be conducted primarily through digital channels, while Lindus Health’s proprietary eClinical platform will facilitate participant pre-screening, data capture, and virtual study visits. Remote monitoring will be supported by wearable and digital health technologies, ensuring real-time and accurate data collection. Together, we are dedicated to pioneering a future where individuals with ME/CFS have access to effective treatments, ultimately enhancing their quality of life and restoring hope for a healthier tomorrow.
The Role of Lindus Health
Lindus Health is an innovative partner in the clinical research landscape, committed to accelerating the development of breakthrough therapies. Their expertise in running decentralized trials and leveraging digital health solutions plays a crucial role in ensuring the success of the ME/CFS study.
As we continue our mission to transform healthcare, we look forward to sharing the findings of this groundbreaking study. Upon completion, we will publish a detailed analysis of the results, reinforcing our commitment to transparency and scientific progress. Stay tuned for further updates as we pioneer the future of health together.
TIEFENBACHER PHARMACEUTICALS is a part of Tiefenbacher Group. We develop and commercialize generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals Launch: Varenicline in UK
Tiefenbacher Pharmaceuticals successfully prepares the launch of Varenicline in the United Kingdom
We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be available and affordable for patients all around the world. That´s why we are thrilled to share that we have successfully prepared the launch of Varenicline in the UnitedKingdom!
WHO has added Varenicline to the list of essential medicines in 2021. This medicine is a cornerstone of the smoking cessation therapy helping patients to stop smoking in a short period of time (12 to 24 weeks).
Nevertheless, the originator brand Champix had to be withdrawn from the market in the same year due to the formation of nitrosamines in the manufacturing process. The European Medicines Agency has set clear quality standards for the product. Those need to be fulfilled before this important medicine could be made accessible again.
Tiefenbacher Pharmaceuticals brings the smoking cessation molecule Varenicline to patients in United Kingdom
In the last years, Tiefenbacher Group has successfully completed the formulation in its laboratories in Hyderabad, India. We are proud that we are the first who meet the European quality criteria. Together with our partners we are ready to be the first supplier that brings back Varenicline to smoking cessation patients in the United Kingdom.
Varenicline Citrate film coated tablets are marketed in the strengths 0,5 mg and 1 mg by our partners. This launch will not only improve the life of patients but also bring significant cost reduction for the healthcare systems. Untreated smoking addiction leads to a variety of follow-up diseases like premature atherosclerosis or coronary artery disease.
This launch reflects our ongoing commitment to providing patients with high-quality, affordable medicines. It is also a testament to the hard work and commitment of our team. We are excited about the positive impact this achievement will make.
In case of inquiries please reach out to licensing@tiefenbacher.com
TIEFENBACHER PHARMACEUTICALS is a part of Tiefenbacher Group. We develop and commercialize generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms (FDF) including highly potent drugs and e-healthcare solutions, please contact us at info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Group finalizing renovation
We are thrilled to announce the completion of the Tiefenbacher Group renovation of our office at the Port of Hamburg.
The finalization of the 4th floor marks a significant milestone, ensuring that our office environment is not only modern and innovative but also truly inspiring.
Our newly completed floor boasts three exceptionally spacious conference rooms with state-of-the-art technology. Each room is featuring large windows that offer breathtaking views of the Elbe River. These rooms are designed to foster creativity and collaboration, providing the perfect setting for important meetings and brainstorming sessions.
In addition to the conference rooms, the floor includes two large open workspaces, a welcoming reception area, several smaller offices, and silence rooms that offer a quiet space for focused work. We have also dedicated a beautiful corridor to honor our founder, Alfred E. Tiefenbacher. Rounding this up with a portrait of him that serves as a reminder of our rich history and the visionary leadership that continues to drive us forward.
The Hamburg office a state-of-the-art workspace
This office modernization reflects our commitment to providing a state-of-the-art workspace that promotes the growth and well-being of our employees. The airy, transparent, and light-flooded interiors of our Hamburg office are intended to encourage innovation, partnership, and team spirit among our staff. These new branding elements integrated into the workspace emphasize our culture of professionalism, openness and the pioneering mentality that characterizes us.
As hybrid working and working from home have become the new normal for many, we are keen to keep our workspace at the cutting edge. We believe that our new premises on the banks of the Elbe offer a great working environment that supports the growth and well-being of our team.
Finally we would like to extend our heartfelt thanks to everyone who contributed to this project and made this transformation possible. We look forward to welcoming you to our new offices soon!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Group wishes you a happy new year!
As 2024 draws to a close, the Tiefenbacher Group wishes you a Happy New Year and likes to share some of the year's highlights with you.
This year we celebrated many achievements: several international launches of prescription medicines, the preparation for Bilastine’s over-the-counter entry in Germany, the renovation of our Hamburg offices, and the construction of new labs and production buildings in Hyderabad, India.
2024, our sustainability efforts have been acknowledged with the EcoVadis Silver Medal on several occasions. Our social projects have not been neglected either: we started our strategic partnership with Pharmacists without Boarders, supported our school in India with several projects, and our employees have spent their social day in charitable institutions in Hamburg. Additionally our team in India spent their social day with collecting donations for the victims of the Rahat flood. And last but not least in December a significant part of our employees have donated a substantial amount for a good cause which got doubled by the management.
Furthermore, we have also been to numerous fairs and events to meet you in person. So we can tell you about our latest product portfolio and how we make pharmaceuticals more affordable, more available, and better than before!
Tiefenbacher Group is already looking very much forward to 2025. In this year, we want to continue to rock our markets by surprising patients with more affordable, more available and better-than-before medicines!
We hope the year 2025 will be as successful and full of unique moments as the past one and we are looking forward to meeting you again in person all over the world!
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on: www.tiefenbachergroup.com
Tiefenbacher Pharmaceuticals, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Laboratories Celebrating End-of-Year Fest
Last week, Tiefenbacher Laboratories celebrated its much-anticipated End-of-Year Party at our R&D and manufacturing site in India.
This annual fest brought together our dedicated employees from Hyderabad and Hamburg to celebrate their incredible contributions throughout the year.
The day began with a series of sports competitions, where participants showcased their skills in:
🏏 Cricket (Men & Women)
⚽ Football
🏐 Volleyball
🏸 Badminton
🎾 Tennikoit
🥄 Lemon Spoon Race
The day continued with an array of cultural activities, including vibrant dance and singing performances as well as engaging skits that showcased creativity and humor. Afterwards the winners of the sporting competitions were honored with trophies and prizes at the ceremony and their team spirit and sportsmanship were recognized.
Our German managing directors Oliver and Kristian as well as our colleague Johanna Böttcher from the Hamburg office were also invited and took part in the wonderful celebration. They enjoyed the event, which was filled with great music that ultimately got everyone on the dance floor.
We are happy to celebrate and connect with our beloved Tiefenbacher Laboratories team. Your dedication and passion drive our success, and this event was a heartfelt way to say thank you.
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDF) including highly potent drugs as well as medical devices and e-health-solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products (including highly potent drugs) and e-health-solutions for global markets, please contact us by email at info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage (FDF) forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com